NEW YORK, April 25, 2023 ‒ Aetion ®, the global leader in real-world evidence (RWE) technology and analytics, is pleased to announce the culmination of the RCT-DUPLICATE demonstration project, with ...

Patients with end-stage renal disease (ESRD) experience extremely high morbidity and mortality, and there are virtually no therapeutic interventions besides dialysis treatment which are proven, in ...

Recent advances in biotechnology and cancer genomics have afforded enormous opportunities for development of more effective anticancer therapies. A key thrust of this modern drug development paradigm ...

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update ...

The What Works Clearinghouse (WWC) identifies studies that provide credible and reliable evidence of a given intervention’s effectiveness. Yet there is a high potential for serious estimation bias ...

CHICAGO – Loxo Oncology Inc.'s announcement that it will seek tissue-agnostic approval for larotrectinib (LOXO-101) based on data that were presented at this year's ASCO meeting came just weeks after ...